JP2020504122A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504122A5
JP2020504122A5 JP2019535810A JP2019535810A JP2020504122A5 JP 2020504122 A5 JP2020504122 A5 JP 2020504122A5 JP 2019535810 A JP2019535810 A JP 2019535810A JP 2019535810 A JP2019535810 A JP 2019535810A JP 2020504122 A5 JP2020504122 A5 JP 2020504122A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
aryl
heteroaryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019535810A
Other languages
English (en)
Japanese (ja)
Other versions
JP7171057B2 (ja
JP2020504122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/058477 external-priority patent/WO2018122775A1/en
Publication of JP2020504122A publication Critical patent/JP2020504122A/ja
Publication of JP2020504122A5 publication Critical patent/JP2020504122A5/ja
Application granted granted Critical
Publication of JP7171057B2 publication Critical patent/JP7171057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019535810A 2016-12-29 2017-12-28 ヘテロアリール化合物およびその使用 Active JP7171057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382672.0 2016-12-29
EP16382672 2016-12-29
PCT/IB2017/058477 WO2018122775A1 (en) 2016-12-29 2017-12-28 Heteroaryl compounds and their use

Publications (3)

Publication Number Publication Date
JP2020504122A JP2020504122A (ja) 2020-02-06
JP2020504122A5 true JP2020504122A5 (cg-RX-API-DMAC7.html) 2021-02-12
JP7171057B2 JP7171057B2 (ja) 2022-11-15

Family

ID=57708486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535810A Active JP7171057B2 (ja) 2016-12-29 2017-12-28 ヘテロアリール化合物およびその使用

Country Status (9)

Country Link
US (2) US11174242B2 (cg-RX-API-DMAC7.html)
EP (1) EP3562811B1 (cg-RX-API-DMAC7.html)
JP (1) JP7171057B2 (cg-RX-API-DMAC7.html)
CN (1) CN110325516A (cg-RX-API-DMAC7.html)
AU (1) AU2017388466B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019013571A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048357A1 (cg-RX-API-DMAC7.html)
IL (1) IL267626B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018122775A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019013571A2 (pt) 2016-12-29 2020-01-07 Minoryx Therapeutics S.L. Compostos heteroarila e seu uso
WO2020104578A2 (en) * 2018-11-21 2020-05-28 University Of Copenhagen Modulators of free fatty acid receptor 1 and their use for treatment of diseases
WO2021105908A1 (en) * 2019-11-25 2021-06-03 Gain Therapeutics Sa Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
US20230103407A1 (en) * 2020-03-10 2023-04-06 University Of Cincinnati Materials and methods for the treatment of gaucher disease
CN117659017A (zh) * 2022-08-25 2024-03-08 北京华益健康药物研究中心 Trpml1/2调节剂化合物、药物组合物及其制备方法和应用
WO2024206067A2 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation Symmetric aminoindole-linked triazine for a dual effect on alpha-synuclein and tau isoform 2n4r fibrillization

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012361A3 (cs) * 1999-01-22 2001-12-12 Elan Pharmaceuticals, Inc. Metoda pro léčení nemoci zprostředkované VLA-4, sloučenina a farmaceutický prostředek
CA2430951A1 (en) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
US20030078271A1 (en) 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
PL369270A1 (en) * 2001-01-31 2005-04-18 H.Lundbeck A/S Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
DE50304983D1 (de) * 2002-10-28 2006-10-19 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
CN1199946C (zh) 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
JP2008535866A (ja) * 2005-04-08 2008-09-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリミジン誘導体
RU2008114378A (ru) 2005-09-13 2009-10-20 Палау Фарма, С.А. (Es) Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
US8138356B2 (en) 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20130023498A1 (en) 2008-02-20 2013-01-24 The Wistar Institute and North Carolina State University MicroRNA Modulators and Method for Identifying and Using the Same
CN102112478A (zh) * 2008-06-10 2011-06-29 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
LT2995306T (lt) 2009-10-19 2019-04-10 Amicus Therapeutics, Inc. Naujos kompozicijos lizosomų kaupimosi sutrikimų profilaktikai ir (arba) gydymui
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
MX368340B (es) 2011-03-18 2019-09-30 Genzyme Corp Inhibidores de glucosilceramida sintasa.
JP6061922B2 (ja) 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
ES2924829T3 (es) 2012-03-27 2022-10-11 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central
JP2015535225A (ja) * 2012-10-24 2015-12-10 グルソックス・バイオテック・アーベー ニコチンアミドアデニンジヌクレオチドリン酸オキシダーゼに関連する状態を処置するためのトリアジン誘導体
EP3027590A1 (en) 2013-07-31 2016-06-08 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
CA2939501C (en) * 2014-02-12 2020-07-07 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
WO2016073895A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
WO2016120808A1 (en) 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof
EP3258937A4 (en) 2015-02-16 2018-10-31 Glucox Biotech AB N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine
WO2016168420A1 (en) 2015-04-15 2016-10-20 Biomarin Pharmaceutical Inc. Methods for treating lysosomal storage disorders
WO2017031116A1 (en) 2015-08-18 2017-02-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of ku70/80 and uses thereof
CN105412114A (zh) * 2015-12-11 2016-03-23 卢璐娇 6-{[4-(2-氟苯基)1-哌嗪基]甲基}-n-(萘基)-1,3,5-三嗪-2,4-二胺在制备血管生成抑制剂中的应用
BR112019013571A2 (pt) 2016-12-29 2020-01-07 Minoryx Therapeutics S.L. Compostos heteroarila e seu uso

Similar Documents

Publication Publication Date Title
JP2020504122A5 (cg-RX-API-DMAC7.html)
AU2016299485B2 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
JP2020519606A5 (cg-RX-API-DMAC7.html)
JP2020504711A5 (cg-RX-API-DMAC7.html)
JP2016534134A5 (cg-RX-API-DMAC7.html)
JP2020503297A5 (cg-RX-API-DMAC7.html)
BR0014649A (pt) Utilização de um produto, medicamento, composto e composição farmacêutica
CN114728910A (zh) 用于fgfr抑制剂的吡唑类衍生物及其制备方法
HUP0401876A2 (hu) Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
JPH11193281A (ja) アデノシンa3受容体拮抗剤およびチアゾール化合物
NO900991D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(l-piperazinyl)-4-fenylcycloalkanopyridin-derivater
JP2008513515A5 (cg-RX-API-DMAC7.html)
RU2005117789A (ru) Производные 4,5-диарилтиазола в качестве лигандов св-1
JP2020533352A5 (cg-RX-API-DMAC7.html)
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
BR112012032813A2 (pt) composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença ou condição.
CN111601797A (zh) 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
JP2014520108A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
JPWO2023195529A5 (cg-RX-API-DMAC7.html)
CA2730471A1 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
CA2618511A1 (en) Novel benzothiazolone derivatives
RU2007116987A (ru) Новые соединения
CA2405408A1 (en) Pyrazole compounds
JP2020111571A5 (cg-RX-API-DMAC7.html)